Orchestra BioMed Stock Price, News & Analysis (NASDAQ:OBIO) $7.95 +0.44 (+5.86%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$7.31▼$7.9950-Day Range$4.42▼$10.3752-Week Range$4.26▼$23.39Volume48,655 shsAverage Volume40,557 shsMarket Capitalization$284.13 millionP/E RatioN/ADividend YieldN/APrice Target$17.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Orchestra BioMed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside120.1% Upside$17.50 Price TargetShort InterestBearish5.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.54) to ($1.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.60 out of 5 starsMedical Sector818th out of 942 stocksSurgical & Medical Instruments Industry86th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingOrchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.50, Orchestra BioMed has a forecasted upside of 120.1% from its current price of $7.95.Amount of Analyst CoverageOrchestra BioMed has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.93% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Orchestra BioMed has recently increased by 1.56%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOrchestra BioMed does not currently pay a dividend.Dividend GrowthOrchestra BioMed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OBIO. Previous Next 2.9 News and Social Media Coverage News SentimentOrchestra BioMed has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Orchestra BioMed this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Orchestra BioMed insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 30.16% of the stock of Orchestra BioMed is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.54) to ($1.81) per share. Previous Next See Top Rated MarketRank™ Stocks Here About Orchestra BioMed Stock (NASDAQ:OBIO)Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in patients indicated for a cardiac pacemaker; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Read More OBIO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OBIO Stock News HeadlinesDecember 8, 2023 | americanbankingnews.comFinancial Comparison: Orchestra BioMed (NASDAQ:OBIO) and Intelligent Bio Solutions (NASDAQ:INBS)November 16, 2023 | finanznachrichten.deOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business UpdateDecember 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. November 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Bicycle Therapeutics (BCYC)November 14, 2023 | uk.finance.yahoo.comOrchestra BioMed Holdings, Inc. (OBIO)November 13, 2023 | finance.yahoo.comOrchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 9, 2023 | finance.yahoo.comOrchestra BioMed to Present at Upcoming Investor ConferencesNovember 7, 2023 | msn.comAxoGen Non-GAAP EPS of $0.01 beats by $0.07, revenue of $41.3M beats by $1.03MDecember 9, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 25, 2023 | finanznachrichten.deOBiO Technology (Shanghai) Corp., Ltd.: OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy ProductOctober 21, 2023 | wsj.comOrchestra BioMed Holdings Inc.October 12, 2023 | seekingalpha.comOrchestra BioMed files prospectus for issuance of up to 1.93M sharesOctober 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Reneo Pharmaceuticals (RPHM), Pulmonx (LUNG) and Orchestra BioMed Holdings (OBIO)September 22, 2023 | finance.yahoo.comLab Notes: Main Line firm spins off company that will focus on OTC product pipelineSeptember 19, 2023 | markets.businessinsider.comOrchestra BioMed Holdings (OBIO) Gets a Buy from LifeSci CapitalSeptember 19, 2023 | markets.businessinsider.comCrude Oil Rises Over 1%; Revance Therapeutics Shares PlummetSeptember 19, 2023 | msn.comWhy Shares of Orchestra BioMed Jumped TuesdaySeptember 19, 2023 | finance.yahoo.comRebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football CoachSeptember 19, 2023 | baystreet.caOrchestra, Medtronic Join ForcesAugust 11, 2023 | finanznachrichten.deOrchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 11, 2023 | finance.yahoo.comOrchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 10, 2023 | msn.comChardan Capital Reiterates Orchestra BioMed Holdings (OBIO) Buy RecommendationAugust 8, 2023 | finance.yahoo.comOrchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent RestenosisAugust 2, 2023 | uk.investing.comOrchestra Biomed Holdings Inc (OBIO)July 31, 2023 | finance.yahoo.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28%June 28, 2023 | finance.yahoo.comWhy Shares of Orchestra BioMed Holdings Jumped WednesdayJune 26, 2023 | finance.yahoo.comOrchestra BioMed Set to Join Russell 3000® and other FTSE Russell IndexesSee More Headlines Receive OBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/09/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OBIO CUSIPN/A CIK1814114 Weborchestrabiomed.com Phone646-597-6980FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$17.50 High Stock Price Target$20.00 Low Stock Price Target$15.00 Potential Upside/Downside+120.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,730,000.00 Net MarginsN/A Pretax Margin-22,322.03% Return on Equity-23.18% Return on Assets-13.60% Debt Debt-to-Equity RatioN/A Current Ratio5.13 Quick Ratio5.13 Sales & Book Value Annual Sales$147,000.00 Price / Sales1,933.09 Cash FlowN/A Price / Cash FlowN/A Book Value($0.62) per share Price / Book-12.82Miscellaneous Outstanding Shares35,744,000Free FloatN/AMarket Cap$284.16 million OptionableNot Optionable Beta0.09 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. David P. Hochman (Age 48)Founder, Chairman of the Board of Directors & CEO Comp: $790kMr. Darren R. Sherman (Age 52)Founder, President, COO & Director Comp: $790kMr. Andrew Lawrence Taylor M.B.A. (Age 52)Chief Financial Officer Ms. Inessa R. WheelerVice President of Strategy & MarketingMr. William Reed Little (Age 52)Executive VP of Corporate Development & Strategy Dr. Yuval Hay Mika D.ScPh.D., GM & CTO of Bioelectronic TherapiesDr. George Papandreou Ph.D.Senior VP & GM of Focal TherapiesDr. Hans-Peter Stoll M.D.Ph.D., Chief Clinical OfficerDr. Avraham Matityahu Fischer M.D. (Age 67)Senior Vice President of Medical Affairs & Innovation Mr. Bob LaughnerSenior Vice President of Regulatory & QualityMore ExecutivesKey CompetitorsAngioDynamicsNASDAQ:ANGOProfound MedicalNASDAQ:PROFCerusNASDAQ:CERSUtah Medical ProductsNASDAQ:UTMDAlpha Tau MedicalNASDAQ:DRTSView All CompetitorsInstitutional OwnershipHarbour Investments Inc.Bought 3,500 shares on 11/16/2023Ownership: 0.010%The Manufacturers Life Insurance Company Bought 5,571 shares on 11/15/2023Ownership: 0.107%California State Teachers Retirement SystemSold 9,301 shares on 11/14/2023Ownership: 0.009%Northern Trust CorpBought 88,804 shares on 11/13/2023Ownership: 0.404%Rhumbline AdvisersBought 4,379 shares on 11/9/2023Ownership: 0.021%View All Institutional Transactions OBIO Stock Analysis - Frequently Asked Questions Should I buy or sell Orchestra BioMed stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OBIO shares. View OBIO analyst ratings or view top-rated stocks. What is Orchestra BioMed's stock price target for 2024? 3 equities research analysts have issued 12-month price objectives for Orchestra BioMed's stock. Their OBIO share price targets range from $15.00 to $20.00. On average, they expect the company's stock price to reach $17.50 in the next year. This suggests a possible upside of 120.1% from the stock's current price. View analysts price targets for OBIO or view top-rated stocks among Wall Street analysts. How have OBIO shares performed in 2023? Orchestra BioMed's stock was trading at $9.12 at the beginning of 2023. Since then, OBIO stock has decreased by 12.8% and is now trading at $7.95. View the best growth stocks for 2023 here. When is Orchestra BioMed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our OBIO earnings forecast. How were Orchestra BioMed's earnings last quarter? Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.01. The business had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.89 million. Who are Orchestra BioMed's major shareholders? Orchestra BioMed's stock is owned by many different retail and institutional investors. Top institutional investors include Charles Schwab Investment Management Inc. (0.43%), Northern Trust Corp (0.40%), TD Asset Management Inc (0.26%), Arkadios Wealth Advisors (0.14%), Bank of New York Mellon Corp (0.11%) and The Manufacturers Life Insurance Company (0.11%). How do I buy shares of Orchestra BioMed? Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:OBIO) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.